Skip to main content
Log in

Targeted therapy for pediatric low-grade glioma

  • Original Article
  • Published:
Child's Nervous System Aims and scope Submit manuscript

Abstract

Purpose

Pediatric low-grade gliomas are the most frequent brain tumors in children. The standard approach for symptomatic unresectable tumors is chemotherapy. Recently, key molecular alterations/pathways have been identified and targeted drugs developed and tested in clinical trials. We describe our institutional experience with MAPK pathway targeted therapy.

Methods

We retrospectively reviewed the medical reports of 23 patients diagnosed with PLGG and treated with either trametinib or dabrafenib at Hospital Sant Joan de Dèu (Barcelona, Spain). Patients with neurofibromatosis were excluded. Objective response rate (ORR) and disease control rate (DCR) were determined using the Response Assessment in Pediatric Neuro-Oncology criteria in low-grade glioma. ORR was defined as the proportion of patients with the best overall response including complete remission (CR) or partial remission (PR). DCR was the sum of the CR, PR, and stable disease (SD) rates.

Results

ORR with trametinib was 0% (95% CI, 0%–23.2%) and DCR was 78.6% (95% CI, 49.2%–95.3%). Eleven patients had SD and three patients presented PD. ORR with dabrafenib was 41.7% (95% CI, 16.5%–71.4%), including four CR and one patient with PR. DCR with dabrafenib was 100% (95% CI, 73.5%–100%); there were seven SD and none PD. Treatment was well tolerated. Only three patients, on trametinib, presented grade 3 adverse effects: leukocytoclastic vasculitis, cheilitis, and bone infection.

Conclusions

Our experience adds to the growing data about the efficacy and tolerability of targeted therapy in patients with PLGG. When present, toxicity is mainly mild-moderate and transient. Ongoing prospective clinical trials are trying to address if its use should be advanced to first-line therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Chen YH, Gutmann DH (2014) The molecular and cell biology of pediatric low-grade gliomas. Oncogene 33(16):2019–2026. https://doi.org/10.1038/onc.2013.148

    Article  CAS  PubMed  Google Scholar 

  2. Bandopadhayay P, Bergthold G, London WB, Goumnerova LC, Morales La Madrid A, Marcus KJ, Guo D, Ullrich NJ, Robison NJ, Chi SN, Beroukhim R, Kieran MW, Manley PE (2014) Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer 61(7):1173–1179

    Article  PubMed  PubMed Central  Google Scholar 

  3. Krishnatry R, Zhukova N, Guerreiro Stucklin AS, Pole JD, Mistry M, Fried I, Ramaswamy V, Bartels U, Huang A, Laperriere N, Dirks P, Nathan PC, Greenberg M, Malkin D, Hawkins C, Bandopadhayay P, Kieran MW, Manley PE, Bouffet E, Tabori U (2016) Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study. Cancer. 122(8):1261–1269

    Article  PubMed  Google Scholar 

  4. Kandels D, Pietsch T, Bison B, Warmuth-Metz M, Thomale UW, Kortmann RD, Timmermann B, Hernáiz Driever P, Witt O, Schmidt R, Gnekow AK (2020) Loss of efficacy of subsequent nonsurgical therapy after primary treatment failure in pediatric low-grade glioma patients—report from the German SIOP-LGG 2004 cohort. Int J Cancer 147:3471–3489

    Article  CAS  PubMed  Google Scholar 

  5. Jones DTW, Kieran MW, Bouffet E, Alexandrescu S, Bandopadhayay P, Bornhorst M, Ellison D, Fangusaro J, Fisher MJ, Foreman N, Fouladi M, Hargrave D, Hawkins C, Jabado N, Massimino M, Mueller S, Perilongo G, Schouten van Meeteren AYN, Tabori U, Warren K, Waanders AJ, Walker D, Weiss W, Witt O, Wright K, Zhu Y, Bowers DC, Pfister SM, Packer RJ (2018) Pediatric low-grade gliomas: next biologically driven steps. Neuro-Oncology 20(2):160–173

    Article  CAS  PubMed  Google Scholar 

  6. Penman CL, Faulkner C, Lowis SP, Kurian KM (2015) Current understanding of BRAF alterations in diagnosis, prognosis and therapeutic targeting in paediatric low grade gliomas. Front Oncol 5(54):1–10

    Google Scholar 

  7. Roth JJ, Santi M, Pollock AN, Harding BN, Rorke-adams LB, Tooke LS et al (2015) Chromosome band 7q34 deletions resulting in KIAA1549-BRAF and FAM131B-BRAF fusions in pediatric low-grade gliomas. Brain Pathol 25(2):182–192

    Article  CAS  PubMed  Google Scholar 

  8. Shin CH, Grossmann AH, Holmen SL, Robinson JP (2015) The BRAF kinase domain promotes the development of gliomas in vivo. Genes Cancer 6(1–2):9–18

    Article  PubMed  PubMed Central  Google Scholar 

  9. Basto D, Trovisco V, Lopes JM, Martins A, Pardal F, Soares P et al (2005) Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol 109(2):207–210

    Article  CAS  PubMed  Google Scholar 

  10. Lassaletta A, Zapotocky M, Mistry M, Ramaswamy V, Honnorat M, Krishnatry R, Guerreiro Stucklin A, Zhukova N, Arnoldo A, Ryall S, Ling C, McKeown T, Loukides J, Cruz O, de Torres C, Ho CY, Packer RJ, Tatevossian R, Qaddoumi I, Harreld JH, Dalton JD, Mulcahy-Levy J, Foreman N, Karajannis MA, Wang S, Snuderl M, Nageswara Rao A, Giannini C, Kieran M, Ligon KL, Garre ML, Nozza P, Mascelli S, Raso A, Mueller S, Nicolaides T, Silva K, Perbet R, Vasiljevic A, Faure Conter C, Frappaz D, Leary S, Crane C, Chan A, Ng HK, Shi ZF, Mao Y, Finch E, Eisenstat D, Wilson B, Carret AS, Hauser P, Sumerauer D, Krskova L, Larouche V, Fleming A, Zelcer S, Jabado N, Rutka JT, Dirks P, Taylor MD, Chen S, Bartels U, Huang A, Ellison DW, Bouffet E, Hawkins C, Tabori U (2017) Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol 35(25):2934–2941

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Mistry M, Zhukova N, Merico D, Rakopoulos P, Krishnatry R, Shago M, Stavropoulos J, Alon N, Pole JD, Ray PN, Navickiene V, Mangerel J, Remke M, Buczkowicz P, Ramaswamy V, Guerreiro Stucklin A, Li M, Young EJ, Zhang C, Castelo-Branco P, Bakry D, Laughlin S, Shlien A, Chan J, Ligon KL, Rutka JT, Dirks PB, Taylor MD, Greenberg M, Malkin D, Huang A, Bouffet E, Hawkins CE, Tabori U (2015) BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol 33(9):1015–1022

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kondyli M, Larouche V, Saint-Martin C, Ellezam B, Pouliot L, Sinnett D et al (2018) Trametinib for progressive pediatric low-grade gliomas. J Neuro-Oncol 140(2):435–444. https://doi.org/10.1007/s11060-018-2971-9

    Article  CAS  Google Scholar 

  13. Nicolaides T, Nazemi KJ, Crawford J, Kilburn L, Minturn J, Gajjar A, Gauvain K, Leary S, Dhall G, Aboian M, Robinson G, Long-Boyle J, Wang H, Molinaro AM, Mueller S, Prados M (2020) Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget. 11(21):1942–1952

    Article  PubMed  PubMed Central  Google Scholar 

  14. Hargrave DR, Bouffet E, Tabori U, Broniscer A, Cohen KJ, Hansford JR, Geoerger B, Hingorani P, Dunkel IJ, Russo MW, Tseng L, Dasgupta K, Gasal E, Whitlock JA, Kieran MW (2019) Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation–positive relapsed or refractory low-grade glioma: results from a phase I/IIa study. Clin Cancer Res 25(24):7303–7311

    Article  CAS  PubMed  Google Scholar 

  15. Perreault S, Larouche V, Tabori U, Hawkin C, Lippé S, Ellezam B et al (2019) A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. BMC Cancer 19(1):1–9

    Article  Google Scholar 

  16. Manoharan N, Choi J, Chordas C, Zimmerman MA, Scully J, Clymer J et al (2020) Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma. J Neuro-Oncol 149(2):253–262. https://doi.org/10.1007/s11060-020-03592-8

    Article  CAS  Google Scholar 

  17. Fangusaro J, Witt O, Hernáiz Driever P, Bag AK, de Blank P, Kadom N et al (2020) Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol 21(6):e305–e316. https://doi.org/10.1016/S1470-2045(20)30064-4

    Article  PubMed  Google Scholar 

  18. Nobre L, Zapotocky M, Ramaswamy V, Ryall S, Bennet J, Alderete D et al (2020) Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition. JCO Precis Oncol 4(4):561–571

    Article  Google Scholar 

  19. Selt F, van Tilburg CM, Bison B, Sievers P, Harting I, Ecker J et al (2020) Response to trametinib treatment in progressive pediatric low-grade glioma patients. J Neuro-Oncol 149(3):499–510. https://doi.org/10.1007/s11060-020-03640-3

    Article  CAS  Google Scholar 

  20. Menzies AM, Long GV (2014) Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin Cancer Res 20(8):2035–2043

    Article  CAS  PubMed  Google Scholar 

  21. Cebollero A, Puértolas T, Pajares I, Calera L, Antón A (2016) Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma. Mol Clin Oncol 5(4):458–462

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Welsh SJ, Corrie PG (2015) Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol 7(2):122–136

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Lacroix J, Wang B (2017) Prospective case series of cutaneous adverse effects associated with dabrafenib and trametinib. J Cutan Med Surg 21(1):54–59

    Article  CAS  PubMed  Google Scholar 

  24. Hauschild A, Grob J, Demidov LV, Jouary T, Gutzmer R, Millward M et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358–365. https://doi.org/10.1016/S0140-6736(12)60868-X

    Article  CAS  PubMed  Google Scholar 

  25. Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS et al (2012) Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol 67(6):1265–1272. https://doi.org/10.1016/j.jaad.2012.04.008

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Peng L, Wang Y, Hong Y, Ye X, Shi P, Zhang J, Zhao Q (2017) Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis. Oncotarget. 8(47):83280–83291

    Article  PubMed  PubMed Central  Google Scholar 

  27. Atkinson V, Long GV, Menzies AM, McArthur G, Carlino MS, Millward M, Roberts-Thomson R, Brady B, Kefford R, Haydon A, Cebon J (2016) Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists. Asia Pac J Clin Oncol 12:5–12

    Article  PubMed  Google Scholar 

  28. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty D (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372(1):30–39

    Article  PubMed  Google Scholar 

  29. Stjepanovic N, Velazquez-Martin JP, Bedard PL (2016) Ocular toxicities of MEK inhibitors and other targeted therapies. Ann Oncol 27(6):998–1005. https://doi.org/10.1093/annonc/mdw100

    Article  CAS  PubMed  Google Scholar 

  30. Olow A, Mueller S, Yang X, Hashizume R, Meyerowitz J, Weiss W, Resnick AC, Waanders AJ, Stalpers LJA, Berger MS, Gupta N, James CD, Petritsch CK, Haas-Kogan DA (2016) BRAF status in personalizing treatment approaches for pediatric gliomas. Clin Cancer Res 22(21):5312–5321

  31. Drobysheva A, Klesse LJ, Bowers DC (2017) Targeted MAPK pathway inhibitors in patients with disseminated pilocytic astrocytomas. J Natl Compr Cancer Netw 15(8):978–982

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Andrés Morales La Madrid.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare that are relevant to the content of this article.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

ESM 1

(PPTX 52 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pérez, J.P.M., Muchart, J., López, V.SM. et al. Targeted therapy for pediatric low-grade glioma. Childs Nerv Syst 37, 2511–2520 (2021). https://doi.org/10.1007/s00381-021-05138-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00381-021-05138-3

Keywords

Navigation